References

  1. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 1986; 29(6):70614. PubMed | Google Scholar

  2. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol. 1998; 25(6):1072-7. PubMed | Google Scholar

  3. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37(4):481-94. Google Scholar

  4. Van Albada-Kuipers GA, Linthorst J, Peeters EA, Breedveld FC, Dijkmans BA, Hermans J, et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum. 1988; 31(5):667-71. PubMed | Google Scholar

  5. Vandenbroucke JP, Kaaks R, Valkenburg HA, Boersma JW, Cats A, Festen JJ, et al. Frequency of infections among rheumatoid arthritis patients, before and after disease onset. Arthritis Rheum. 1987;30(7): 810-3. PubMed | Google Scholar

  6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American rheumatism association1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. PubMed | Google Scholar

  7. Villeneuve E, Nam J, Emery P. Rev Bras Reumatol. 2010 ACR-EULAR classification criteria for rheumatoid arthritis. 50(5):481-3. PubMed | Google Scholar

  8. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, et al. Classification criterai for sjogren?s syndrome : a revised version of european criterai proposed by the American and European Consensus Group. Ann Rheum Dis. 2002; 61(6): 554-. PubMed | Google Scholar

  9. J Morel, B Combe. Polyarthrite rhumatoïde. La revue du praticien. 2006; 56(5):553-62. PubMed | Google Scholar

  10. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study. Arthritis and Rheum. 2002; 46(9):2287-93. PubMed | Google Scholar

  11. Doran MF, Crowson CS, Pond GR, O'Fallon WM, et al. Predictors of Infection in Rheumatoid Arthritis. Arthritis and rheumatism. September 2002; 46(9): 2294-2300. PubMed | Google Scholar

  12. Smitten AL, Choi HK, Hochberg MC, Suissa S, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008; 35(3):387-93. PubMed | Google Scholar

  13. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994; 96(2): 115-23. PubMed | Google Scholar

  14. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989; 11(6): 954-63. PubMed | Google Scholar

  15. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum. 2000; 43(7): 1488-95. PubMed | Google Scholar

  16. Coblyn JS. Infections, drugs, and rheumatoid arthritis. What have we learned? J Rheumatol 2008. http://jrheum.org/content/35/3/375.full.pdf. Accessed 26th September 2013.

  17. Van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum, Dis. 1994; 53(4): 224-8. PubMed | Google Scholar

  18. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003; 3(3): 140-55. PubMed | Google Scholar

  19. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54(5): 1390-400. PubMed | Google Scholar

  20. Van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013; 72(9):1496-502. Google Scholar

  21. Xavier Mariette, Thao Pham, Jean Sibilia, et coordinateurs de l'ensemble des experts. Fiches pratiques du Club Rhumatismes et Inflammation (CRI) 2012. Prise en charge pratique des patients sous rituximab. http://www.cri-net.com/recherche/fichespratiques/index_rituximab.asp. Accessed 27th September 2013.

  22. Smolen J, Baulieu AD, Dikranian A et al. Safety of Tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum. 2008; 58(Suppl): S-784. PubMed | Google Scholar